Search Results - Padda, S.K

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    141P Chemotherapy with or without immunotherapy or bevacizumab for EGFR-mutated lung cancer after progression on osimertinib

    141P Chemotherapy with or without immunotherapy or bevacizumab for EGFR-mutated lung cancer after progression on osimertinib by White, M., Neal, J.W., Gardner, R.M., Cunanan, K.M., Das, M., Padda, S.K., Ramchandran, K., Chen, T.T., Wakelee, H.

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    MO01.01 Durvalumab for Patients with Stage III EGFR-Mutated Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy

    MO01.01 Durvalumab for Patients with Stage III EGFR-Mutated Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy by Aredo, J.V., Hellyer, J.A., Neal, J.W., Padda, S.K., McCoach, C.E., Riess, J.W., Cabebe, E.C., Loo, B.W., Diehn, M., Wakelee, H.A.

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    401 POSTER A phase I study of enzastaurin (ENZ), an oral PKC inhibitor, in combination with erlotinib (ERL) administered orally daily to patients with advanced solid malignancies

    401 POSTER A phase I study of enzastaurin (ENZ), an oral PKC inhibitor, in combination with erlotinib (ERL) administered orally daily to patients with advanced solid malignancies by Wakelee, H.A, Padda, S.K, Chhatwani, L, San Pedro-Salcedo, M, Krupitskaya, Y, Musib, L, Latz, J.E

    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Responding to COVID-19 pandemic: Why a strong health system is required

    Responding to COVID-19 pandemic: Why a strong health system is required by Dikid, Tanzin, Chaudhary, Sushma, Goel, Kapil, Padda, Preeti, Sahu, Rajesh, Kumar, Tripurari, Jain, S, Singh, S, Narain, Jai

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: